viral
infect
begin
attach
virion
host
cell
process
requir
specif
interact
protein
expos
surfac
viru
particl
one
sever
receptor
plasma
membran
host
cell
fig
interact
trigger
entri
viru
particl
cell
dissoci
nucleocapsid
ultim
releas
viral
genom
use
revers
transcript
integr
case
hiv
rna
synthesi
exampl
hepat
b
viru
hbv
directli
protein
product
hcv
fig
viral
protein
togeth
host
cell
factor
catalys
amplif
viral
genom
packag
progeni
virion
releas
cell
initi
new
round
infect
virus
requir
host
cell
factor
nearli
everi
step
life
cycl
requir
host
depend
factor
hdf
potenti
drug
target
ideal
moder
reduct
hdf
abund
avail
would
alreadi
substanti
impair
viru
product
hdf
would
nonessenti
host
cell
surviv
would
reduc
likelihood
cytotox
accordingli
inhibitor
target
earli
stage
viral
replic
block
bind
viru
particl
host
cell
receptor
emerg
promis
approach
supplementari
inform
tabl
entri
inhibitor
regard
entri
inhibitor
past
two
decad
progress
made
treatment
infect
hiv
type
entri
viru
requir
interact
primari
receptor
one
two
chemokin
receptor
act
coreceptor
cxcchemokin
receptor
ccchemokin
receptor
fig
wherea
express
cell
promot
entri
celltrop
express
macrophag
popul
cell
promot
entri
macrophagetrop
strain
intriguingli
individu
certain
mutat
resist
infect
strain
predomin
earli
stage
infect
wherea
strain
emerg
later
stage
thu
qualifi
attract
target
antagonist
lock
receptor
non
permiss
conform
therebi
dampen
coreceptor
function
concept
origin
establish
vitro
translat
clinic
use
maraviroc
selzentrycelsentri
pfizer
approv
firstinclass
inhibitor
expect
hdt
resist
maraviroc
low
given
import
hiv
infect
maraviroc
becom
compon
apart
virolog
benefit
maraviroc
also
found
increas
number
cell
patient
suggest
addit
immunolog
underli
mechan
unclear
could
due
involv
immun
regul
howev
clinic
use
maraviroc
limit
given
restrict
virus
precis
hiv
type
delay
onset
treatment
caus
therapi
failur
viru
tropism
chang
patient
accordingli
companion
diagnosi
individu
treatment
requir
select
hdt
entri
inhibitor
hepat
virus
anoth
exampl
entri
inhibitor
investig
agent
myrcludex
b
peptid
deriv
larg
surfac
glycoprotein
hbv
supplementari
inform
tabl
peptid
bind
cell
surfac
molecul
sodium
taurochol
cotransport
polypeptid
ntcp
requir
product
hbv
block
viral
entri
extrem
high
potenc
approxim
pm
fig
intriguingli
entri
receptor
also
exploit
hepat
viru
hdv
satellit
viru
requir
surfac
glycoprotein
hbv
viru
particl
format
review
ref
thu
hdv
consist
associ
hbv
coinfect
respons
sever
form
viral
induc
liver
diseas
peculiar
biolog
myrcludex
b
also
block
entri
valu
myrcludex
b
hbv
hdv
entri
inhibit
compar
lower
bile
salt
transport
inhibit
suggest
viru
entri
block
dose
minor
effect
physiolog
function
ntcp
encourag
result
clinic
trial
conduct
demonstr
excel
toler
even
high
dose
myrcludex
moreov
phase
ibiia
clinic
trial
myrcludex
b
monotherapi
patient
chronic
coinfect
reveal
strong
reduct
hdv
rna
serum
level
normal
liver
enzym
marker
liver
cell
damag
also
synergist
antivir
effect
hdv
hbv
level
patient
treat
combin
myrcludex
b
polyethylen
glycolconjug
pegyl
interferon
myrcludex
b
receiv
orphan
drug
statu
european
medicin
agenc
ema
us
food
drug
administr
fda
clinic
trial
ongo
myrcludex
b
maraviroc
illustr
entri
inhibit
promis
target
hdt
support
broad
applic
hdt
strategi
recent
identif
entri
molecul
ebola
viru
lassa
viru
picornavirus
provid
ideal
start
point
develop
hdt
threaten
pathogen
target
hdf
requir
hcv
replic
apart
target
entri
receptor
hdf
requir
viral
replic
equal
attract
drug
target
one
exampl
host
cell
chaperon
cyclophilin
cypa
use
repliconbas
assay
found
immunosuppress
drug
cyclosporin
csa
potent
inhibit
hcv
bind
therebi
sequest
cypa
subsequ
studi
identifi
cypa
primari
hdf
promot
hcv
cypa
like
requir
proper
assembl
activ
hcv
replicas
complex
sequestr
render
replicas
howev
complex
inhibit
protein
phosphatas
calcineurin
requir
cell
activ
thu
caus
immunosuppress
effect
therefor
nonimmunosuppress
cyp
antagonist
mostli
deriv
csa
design
includ
alisporivir
previous
known
debio
although
phase
phase
ii
clinic
trial
conduct
alisporivir
demonstr
inhibit
hcv
across
differ
genotyp
high
genet
barrier
clinic
develop
compound
pursu
presum
due
rapid
develop
directact
antivir
drug
daa
hcv
howev
cypa
host
cell
factor
use
virus
differ
famili
suggest
cypa
antagonist
potenti
develop
broadspectrum
antivir
although
natur
preexist
mutat
hiv
capsid
protein
cypa
interact
partner
would
limit
broad
clinic
use
compound
class
cypaknockout
mice
human
cell
fulli
therefor
possibl
toxic
associ
cypa
inhibit
low
anoth
exampl
hdf
promot
viral
replic
mirna
preferenti
express
hepatocyt
primari
host
cell
hcv
regul
lipid
metabol
also
bind
sever
region
hcv
genom
notabl
two
region
close
end
stimul
rna
soon
discoveri
hdf
hcv
antisensebas
oligonucleotid
approach
known
antagomir
develop
sequest
infect
cell
therebi
blunt
hcv
replic
approach
well
toler
vitro
vivo
impos
high
genet
barrier
howev
studi
mice
identifi
mirna
tumour
rais
concern
inhibit
moreov
given
challeng
deliveri
antagomir
best
knowledg
one
clinic
candid
regulu
therapeut
nacetylgalactosamineconjug
oligonucleotid
antagon
target
hepatocyt
pursu
combin
differ
approv
investig
first
approv
ifnfre
daabas
therapi
chronic
hepat
c
late
earli
ifn
therapi
primarili
use
treatment
patient
infect
hcv
countri
unabl
afford
highcost
daa
treatment
still
use
cell
treat
cytokin
mount
antivir
state
thu
protect
viral
infect
ifn
simultan
import
stimulatori
effect
adapt
immun
respons
addit
new
strategi
current
emerg
base
use
individu
engin
cell
design
break
persist
viru
infect
activ
immun
exogen
ifn
hcv
hbv
hiv
sever
recombin
ifn
licens
treatment
patient
chronic
hepat
b
hepat
c
supplementari
inform
tabl
includ
ifn
recombin
synthet
type
ifn
recombin
roferona
intron
must
administ
subcutan
inject
sever
time
week
well
pegasi
pegintron
inject
week
success
therapi
measur
sustain
virolog
respons
svr
consider
increas
pegifn
combin
ribavirin
primarili
owe
prevent
viru
relaps
therapi
multipl
paramet
affect
svr
rate
includ
high
bodi
mass
index
liver
cirrhosi
genotyp
infect
addit
polymorph
gene
encod
one
type
iii
ifn
also
known
highli
predict
outcom
therapi
well
acut
underli
reason
clearli
major
limit
ifnbas
therapi
numer
side
effect
includ
influenzalik
symptom
fever
fatigu
depress
bone
marrow
suppress
exacerb
autoimmun
mainli
due
ribavirin
haemolyt
anaemia
side
effect
particularli
pronounc
ifn
discontinu
aim
reduc
system
effect
clinic
trial
conduct
express
receptor
ifn
limit
mucos
epitheli
cell
human
howev
svr
rate
patient
chronic
hepat
c
treat
similar
although
extrahepat
advers
event
less
frequent
patient
treat
given
compar
efficaci
type
iii
type
ifn
presum
also
due
rapid
develop
ifnfre
treatment
modal
clinic
develop
chronic
hepat
c
pursu
also
approv
treatment
adult
chronic
infect
hbv
howev
disappointingli
low
svr
rate
achiev
defin
loss
hbv
surfac
antigen
hbsag
without
product
hbsagspecif
antibodi
refer
hbsag
seroconvers
sustain
control
coval
close
circular
dna
cccdna
liver
fig
nondetect
viral
dna
although
combin
hbvspecif
nucleosid
analogu
enhanc
svr
rate
overal
respons
still
seem
depend
chosen
nucleosid
despit
drawback
certain
advantag
current
avail
chemotherapi
notabl
lack
drug
resist
major
concern
especi
lamivudin
finit
treatment
cours
usual
week
induct
durabl
virolog
respons
particularli
hbsag
seroconvers
also
shown
antivir
activ
ref
howev
area
research
somewhat
neglect
role
ifn
control
hiv
infect
recent
receiv
increas
exampl
administr
rhesu
macaqu
model
infect
pathogen
strain
simian
immunodefici
viru
siv
prevent
system
infect
continu
treatment
dampen
host
ifn
respons
concomit
reduc
antivir
gene
addit
block
type
ifn
receptor
reduc
antivir
gene
express
enhanc
siv
replic
spread
acceler
cell
interestingli
phase
ii
clinic
trial
patient
infect
reveal
signific
albeit
moder
reduct
plasma
viral
load
week
observ
suggest
administr
supraphysiolog
level
ifn
patient
infect
help
control
viru
replic
howev
develop
numer
strategi
avoid
detect
pattern
recognit
receptor
block
ifninduc
restrict
factor
thu
limit
antihiv
activ
moreov
increas
activ
seem
contribut
immun
activ
immun
dysfunct
hivposit
patient
therefor
dampen
product
although
may
detriment
effect
suppress
hiv
replic
might
reduc
immun
activ
thu
sever
diseas
activ
endogen
innat
immun
respons
via
tlr
variou
approach
develop
boost
endogen
innat
ifn
respons
reli
activ
tolllik
receptor
tlr
one
tlr
agonist
approv
antivir
therapi
imidazoquinolin
imiquimod
imiquimod
given
topic
cream
formul
local
treatment
extern
genit
perian
wart
frequent
caus
infect
human
papillomavirus
hpv
imiquimod
sens
trigger
product
variou
cytokin
notabl
tumour
necrosi
factor
tnf
caus
reduct
viral
load
wart
addit
imiquimod
activ
langerhan
cell
migrat
local
lymph
node
promot
adapt
immun
treatment
durat
maximum
week
clearanc
rate
recurr
rate
enhanc
cellular
immun
infect
major
challeng
success
control
hiv
infect
persist
provir
integr
dna
rest
cell
latenc
reservoir
fig
pronounc
immun
suppress
result
infect
differ
strategi
current
pursu
tackl
challeng
includ
shock
kill
approach
latent
reactiv
cell
allow
kill
cell
immun
effector
one
exampl
stimul
rigi
pathway
approv
retino
acid
deriv
acitretin
treatment
activ
hiv
transcript
rigi
express
turn
sens
hiv
rna
thu
mount
ifn
respons
preferenti
induc
apoptosi
hivinfect
although
earli
clinic
studi
drug
acitretin
trigger
transcript
provir
genom
rais
hope
strategi
use
revers
latenc
extent
strategi
reduc
viral
reservoir
size
remain
determin
hope
achiev
hiv
erad
immunebas
therapi
reactiv
famou
berlin
howev
aim
function
cure
immun
control
hiv
without
erad
seem
realist
one
approach
use
immun
cell
engin
express
molecularli
clone
cell
receptor
recogn
hiv
epitop
howev
approach
limit
mani
highli
effect
cell
identifi
patient
recogn
hiv
epitop
context
uncommon
human
leukocyt
antigen
hla
allel
therefor
applic
major
infect
individu
common
hla
moreov
owe
high
level
hiv
genom
variabl
particularli
patient
longterm
infect
latent
hiv
infect
compris
escap
mutant
target
cell
limit
overcom
use
cell
express
chimer
antigen
receptor
car
review
ref
howev
despit
promis
vitro
vivo
result
clinic
valu
approach
hivinfect
individu
remain
determin
activ
immun
releas
immun
suppress
hcv
hbv
hiv
chronic
hepat
b
lead
exhaust
cell
induc
increas
express
checkpoint
inhibitor
program
cell
death
ligand
immun
effector
cell
mous
model
hepat
b
therapi
antibodi
increas
hbcagspecif
interferon
gamma
product
intrahepat
cell
revers
exhaust
cell
phenotyp
led
clearanc
potenti
efficaci
checkpoint
blockad
hepat
b
underscor
addit
studi
show
effect
chronic
viral
infect
exampl
treatment
hcvinfect
chimp
antibodi
enhanc
antivir
cell
respons
reduc
similarli
treatment
sivinfect
macaqu
antibodi
led
signific
reduct
plasma
viral
load
prolong
antimicrobi
capac
macrophag
enhanc
activ
cytokin
vitamin
factor
stimul
cell
autonom
respons
drive
product
antimicrobi
peptid
amp
fig
supplementari
inform
tabl
immuneenhanc
strategi
usual
exert
pleiotrop
effect
integr
stimul
antimicrobi
immun
rectif
pathway
block
alter
mtb
besid
macrophag
dendrit
cell
dc
neutrophil
also
harbour
mtb
howev
hdt
approach
target
cell
far
envisag
activ
myeloid
cell
vitamin
tb
mix
effect
macrophag
report
vitamin
vitamin
mechanist
vitamin
induc
amp
trigger
ro
product
promot
autophagi
infect
amp
induct
potenti
coadministr
histon
deacetylas
inhibitor
fig
although
previou
clinic
trial
assess
benefit
vitamin
tb
provid
inconclus
sever
trial
vitamin
adjunct
tb
chemotherapi
notabl
firstlin
drug
microbicid
effect
vitamin
recogn
attribut
direct
effect
well
modul
host
immun
vitamin
deriv
notabl
alltran
retino
acid
restrict
mtb
growth
macrophag
induc
phagosom
rat
mice
alltran
retino
acid
reduc
mtb
modul
cellular
immun
inflamm
supplement
vitamin
shown
benefici
outcom
care
select
minim
effect
dosag
vitamin
may
form
basi
hdt
tb
cytokinemedi
activ
myeloid
cell
tb
sever
cytokin
notabl
tnf
stimul
antimicrobi
activ
macrophag
fig
promot
phagosom
matur
autophagi
tnf
augment
respons
upregul
rosmedi
kill
increas
amp
synthesi
upregul
tnf
receptor
tnfr
express
restrict
product
type
ifn
primarili
antagonist
tb
howev
hyperinflamm
downstream
excess
cytokin
stimul
promot
diseas
exacerb
see
high
dose
tnf
caus
necroptot
macrophag
death
extracellular
bacteri
replic
current
cytokinebas
hdt
approach
mostli
involv
modul
tnf
exampl
deliveri
aerosol
patient
tb
shown
reduc
time
sputum
convers
without
consist
improv
chest
radiolog
small
trial
carri
cohort
patient
drugresist
tb
adjunct
therapi
addit
facilit
bacteri
kill
improv
lung
howev
cytokinebas
hdt
strategi
modul
tnf
adjunct
canon
chemotherapi
seem
promis
consider
shorten
therapi
durat
improv
patholog
limit
tb
relaps
experiment
model
detail
wherea
type
ifn
includ
qualifi
hdt
sever
viral
infect
seem
counterintuit
bacteri
diseas
tb
given
associ
diseas
howev
given
adjunct
convent
might
provid
interest
treatment
option
resuscit
dormant
mtb
replic
bacilli
suscept
first
secondlin
tb
drug
exampl
isoniazid
rifampin
fluoroquinolon
shock
kill
approach
current
explor
hiv
infect
also
consid
difficulttotreat
form
tb
amend
immun
suppress
tb
express
inhibitori
molecul
upregul
persist
antigen
exposur
occur
chronic
infect
includ
tb
cancer
signal
via
inhibit
cell
prolifer
cytokin
product
induc
lymphocyt
apoptosi
impair
cell
immun
promot
mtb
replic
subsequ
tissu
damag
build
impress
success
achiev
cancer
checkpoint
blockad
consid
tb
therapi
fig
includ
monoclon
antibodi
mab
specif
nivolumab
pembrolizumab
cytotox
lymphocyt
associ
protein
ipilimumab
cell
express
gradual
decreas
canon
chemotherapi
concurr
increas
cell
moreov
express
report
patient
tb
link
impair
cell
natur
killer
nkt
cell
vitro
treatment
mab
cell
cultur
deriv
patient
tb
reduc
immunosuppress
block
cell
apoptosi
restor
product
trigger
kill
mtbinfect
similarli
increas
surfac
express
also
report
checkpoint
receptor
found
highli
express
cell
nk
cell
lung
nonhuman
primat
progress
activ
tb
anim
observ
suggest
chang
express
pattern
influenc
diseas
outcom
mtb
replic
final
blockad
anoth
checkpoint
receptor
cell
increas
propens
myeloid
cell
kill
mtb
effect
link
increas
product
cell
increas
product
mtbinfect
moreov
releas
cell
exhaust
caus
blockad
improv
mtb
control
mice
chronic
infect
howev
intervent
use
checkpoint
inhibitor
gener
warrant
caution
block
inhibitori
effect
cell
therebi
increas
capac
lunghom
subset
cell
caus
extens
lung
patholog
murin
model
final
therapi
reactiv
suggest
checkpoint
blockad
consid
adjunct
canon
tb
chemotherapi
releas
immun
suppress
also
achiev
cellular
therapi
mesenchym
stem
cell
msc
although
msc
may
use
nich
dormant
propens
msc
induc
regulatori
phenotyp
dc
cell
promot
tissu
repair
render
attract
tool
hdt
safeti
approach
demonstr
phase
trial
patient
multidrugresist
tb
mdr
tb
extens
drugresist
tb
xdr
tb
receiv
infus
singl
dose
autolog
higher
cure
rate
radiolog
improv
observ
small
cohort
studi
compris
patient
mdr
deliveri
msc
readi
enter
phase
ii
clinic
trial
adjunct
therapi
drugresist
cytokin
therapi
immunosuppress
phase
sepsi
although
earli
death
sepsi
often
due
cytokinemedi
hyperinflamm
numer
studi
provid
compel
evid
sepsi
protract
last
longer
day
evolv
highli
immunosuppress
major
septic
death
occur
new
immunoadjuv
therapi
need
restor
host
immun
improv
current
one
activ
area
sepsi
fig
supplementari
inform
tabl
two
immuneenhanc
cytokin
alreadi
undergon
small
therapeut
trial
sepsi
colonystimul
factor
gmcsf
gmcsf
stimul
gener
granulocyt
monocyt
macrophag
predomin
function
activ
monocyt
macrophag
although
small
earli
studi
gmcsf
patient
protract
sepsi
seem
subsequ
trial
fail
demonstr
consist
recent
investig
target
therapi
gmcsf
patient
immunosuppress
phase
studi
patient
sepsi
low
monocyt
hladr
express
gmcsf
therapi
shorten
durat
mechan
ventil
improv
sever
ill
score
reduc
length
intens
care
unit
icu
hospit
gmcsf
also
efficaci
studi
immunosuppress
paediatr
patient
sepsi
identifi
measur
ex
vivo
wholeblood
lipopolysaccharid
lp
stimul
tnf
gmcsf
administr
patient
improv
ex
vivo
lpsstimul
wholeblood
tnf
product
decreas
risk
hospitalacquir
infect
base
encourag
result
multicentr
trial
gmcsf
sepsi
current
also
receiv
renew
interest
hdt
patient
immunosuppress
phase
sepsi
multicentr
trial
trauma
patient
mani
develop
sepsi
reveal
patient
treat
fewer
infectionrel
death
also
fewer
overal
death
report
studi
nine
patient
sepsi
decreas
monocyt
hladr
express
reduc
ex
vivo
lpsstimul
wholeblood
tnf
treat
eight
patient
benefit
restor
monocyt
function
surviv
septic
also
test
eight
patient
invas
fungal
infect
markedli
improv
monocyt
hladr
express
enhanc
abil
leukocyt
produc
proinflammatori
cytokin
trial
immunosuppress
patient
bacteri
sepsi
perhap
excit
immunoadjuv
agent
sepsi
cytokin
essenti
surviv
cell
multipl
benefici
effect
host
immun
includ
prolifer
activ
cell
also
increas
surfac
express
cell
adhes
molecul
therebi
facilit
traffick
cell
site
infect
also
counteract
sepsisinduc
apoptosi
lymphocyt
antiapoptot
effect
particularli
import
sever
deplet
immun
effector
cell
includ
cell
b
cell
dc
pathophysiolog
hallmark
multipl
studi
independ
laboratori
shown
improv
surviv
variou
clinic
relev
anim
model
importantli
shown
effect
revers
cell
dysfunct
circul
immun
cell
patient
septic
far
given
patient
treatment
variou
disord
consist
increas
circul
absolut
lymphocyt
count
well
patient
aid
restor
gastrointestinalassoci
lymphoid
tissu
lead
decreas
circul
marker
effect
may
also
particularli
help
patient
sepsi
loss
gut
barrier
integr
sepsi
thought
facilit
transloc
bacteria
andor
lp
circul
therebi
drive
inflammatori
respons
also
administ
compassion
basi
patient
lymphopenia
john
cunningham
jc
virusinduc
progress
multifoc
leukoencephalopathi
set
increas
lymphocyt
count
decreas
jc
viru
load
multicentr
clinic
trial
sepsi
current
checkpoint
blockad
boost
host
immun
sepsi
anoth
highli
promis
therapi
sepsi
blockad
fig
supplementari
inform
tabl
postmortem
studi
patient
sepsi
show
find
consist
cell
exhaust
includ
upregul
immun
cell
sever
impair
cytokin
importantli
multipl
independ
group
report
overexpress
circul
cell
patient
sepsi
incub
peripher
blood
mononuclear
cell
specif
antibodi
restor
impair
cytokin
product
decreas
sepsisinduc
moreov
anim
model
sepsi
shown
delay
administr
antibodi
improv
surviv
given
surpris
overlap
immunolog
deficit
cancer
remark
success
inhibit
cancer
strong
rational
trial
antibodi
sepsi
small
multicentr
dose
safeti
trial
patient
sepsi
recent
immunomodulatori
agent
boost
host
immun
sepsi
anoth
encourag
approach
boost
immun
patient
sepsi
treatment
thymosin
acid
polypeptid
origin
deriv
mous
thymic
extract
supplementari
inform
tabl
although
exact
mechan
action
thymosin
unknown
current
thought
function
part
tlr
agonist
thymosin
known
enhanc
cell
dc
function
increas
product
improv
antibodi
similar
treatment
inhibitor
thymosin
shown
benefit
treatment
cancer
infecti
diseas
thymosin
show
efficaci
improv
surviv
multicentr
random
control
trial
patient
sepsi
compar
patient
treat
placebo
patient
treat
thymosin
increas
monocyt
hlaantigen
relat
dr
express
decreas
base
result
larger
multicentr
trial
thymosin
sepsi
devast
consequ
viral
infect
frequent
aris
excess
often
uncontrol
releas
proinflammatori
cytokin
cytokin
storm
trigger
multipl
mechan
includ
hyperactiv
tlr
exampl
includ
dengu
haemorrhag
fever
dengu
shock
syndrom
often
caus
secondari
infect
heterolog
serotyp
dengu
viru
denv
seriou
case
character
uncontrol
hyperproduct
cytokin
chemokin
tnf
ifn
cc
motif
chemokin
cxc
motif
chemokin
ultim
lead
vascular
leakag
shock
key
driver
cytokin
storm
seem
highlevel
viraemia
ligat
complex
myeloid
mast
cell
secret
version
viral
protein
drive
excess
proinflammatori
respons
reduc
antiinflammatori
one
bind
induc
product
cytokin
detect
cours
sever
dengu
diseas
enhanc
vascular
block
activ
antagonist
antibodi
markedli
reduc
vascular
leakag
vitro
mous
model
denv
moreov
autophagi
induct
endotheli
cell
seem
requir
vascular
leakag
block
autophagi
final
denv
also
promot
vascular
leakag
induc
express
enzym
sialidas
heparanas
degrad
glycocalyx
layer
line
endothelium
lumin
side
thu
diminish
barrier
function
enhanc
fluid
although
best
knowledg
clinic
trial
yet
conduct
result
hold
great
promis
suppress
exacerb
inflamm
target
ligand
receptor
altern
strategi
hdtbase
symptomat
treatment
sever
dengu
diseas
base
immunosuppress
therapi
steroid
prednisolon
far
met
limit
concept
modul
inflamm
also
evalu
influenza
viru
infect
cytokin
storm
caus
acut
sometim
fatal
immunemedi
pulmonari
injuri
propos
acut
lung
injuri
trigger
infect
respiratori
virus
bacteria
induc
via
ro
product
pathogen
oxid
lipid
activ
induc
cytokin
consist
mous
mutant
protect
lethal
challeng
mouseadapt
influenza
viru
notabl
antagonist
eritoran
investig
drug
treatment
sever
sepsi
consist
decreas
lung
patholog
clinic
symptom
variou
vivo
influenza
encourag
result
togeth
wellestablish
safeti
profil
eritoran
observ
given
day
influenza
viru
infect
mice
qualifi
compound
interest
candid
prevent
sever
influenza
sever
altern
strategi
suppress
influenza
virusinduc
cytokin
storm
current
pursu
one
approach
base
agonist
receptor
aalr
compound
reduc
mortal
influenzainfect
mice
reduc
mortal
given
combin
neuraminidas
inhibitor
antiinflammatori
effect
aalr
mediat
least
part
limit
autoamplif
loop
plasmacytoid
dc
main
produc
cytokin
cyclooxygenas
cox
catalys
convers
arachidon
acid
prostaglandin
modul
immun
respons
inflamm
hdt
target
sever
influenza
benefici
effect
report
inhibitor
target
combin
two
inhibitor
celecoxib
mesalazin
neuraminidas
inhibitor
zanamivir
studi
tripl
regimen
surviv
rate
mice
infect
highli
lethal
influenza
viru
strain
significantli
improv
p
surviv
time
p
inflamm
marker
p
rel
anim
receiv
neuraminidas
howev
systemat
evalu
treatment
modal
patient
infect
influenza
viru
still
lack
statin
hdt
assess
clinic
trial
patient
infect
influenza
viru
antiinflammatori
properti
result
approach
antiinflammatori
treatment
base
agonist
peroxisom
proliferatoractiv
consid
promis
target
among
three
ppar
subtyp
sever
studi
mous
model
shown
agonist
decreas
inflamm
influenza
whether
approach
effect
human
remain
determin
increas
evid
suggest
neutrophil
major
role
sever
lung
patholog
influenza
viru
infect
although
cell
contribut
protect
influenza
viru
infect
heighten
neutrophil
recruit
correl
virul
given
influenza
viru
reason
inhibitor
neutrophil
chemotaxi
develop
danirixin
clinic
advanc
inhibitor
chemokin
receptor
drive
neutrophil
migrat
danirixin
develop
treatment
chronic
obstruct
pulmonari
diseas
found
well
toler
induc
major
safeti
base
result
phase
ii
clinic
trial
current
recruit
patient
receiv
danirixin
either
alon
combin
neuraminidas
inhibitor
oseltamivir
therapi
influenza
viru
infect
tb
pathophysiolog
character
nonresolv
inflamm
consequ
host
failur
elimin
mtb
inflammatori
pathway
involv
pro
antiinflammatori
mediat
primarili
cytokin
lipid
sequenti
turn
accordingli
mechan
restrict
promot
inflamm
relev
distinct
diseas
stage
specif
infect
site
imbal
respons
rather
sole
exacerb
proinflammatori
respons
characterist
featur
tb
differ
form
lesion
solid
fibrot
miner
caseat
granuloma
well
caviti
foci
pneumonia
coexist
within
even
within
singl
lesion
inflammatori
mediat
segreg
distinct
therefor
concurr
applic
pro
antiinflammatori
intervent
may
becom
necess
therapi
concept
spatiotempor
coexist
hyper
hypoinflamm
pose
great
challeng
bare
begun
address
current
hdt
approach
compris
small
molecul
biolog
target
anti
proinflammatori
pathway
adjunct
measur
tb
therapi
fig
supplementari
inform
tabl
target
eicosanoid
tb
metabolit
arachidon
acid
modul
inflamm
cell
death
immun
investig
hdt
cox
product
prostaglandin
proapoptot
eicosanoid
protect
necrot
cell
death
mycobacteri
mtb
skew
arachidon
acid
metabol
pathway
toward
lipoxygenas
lox
activ
gener
pronecrot
lipoxin
leukotrien
modul
axi
zileuton
clinic
licens
inhibitor
treatment
asthma
nasal
applic
restrict
lung
patholog
murin
fig
combin
therapi
zileuton
boost
cytoprotect
product
limit
type
ifn
product
restrict
mtb
replic
balanc
level
probabl
involv
success
control
mtb
ltbi
compar
activ
tb
activ
tb
concentr
abund
correl
extent
tissu
damag
mediat
ltbi
earli
product
seem
essenti
protect
wherea
heighten
level
later
stage
infect
impair
immun
defenc
promot
progress
cox
inhibitor
given
alon
combin
canon
tb
drug
limit
bacillari
load
prolong
surviv
tbsuscept
mice
addit
ibuprofen
direct
antitubercular
fig
nonsteroid
antiinflammatori
drug
nsaid
ibuprofen
inhibit
product
enhanc
gener
addit
effect
mtbinduc
cell
death
also
show
antiinflammatori
function
nsaid
limit
pge
releas
induc
lipoxin
product
lower
tnf
thu
like
amelior
local
inflamm
certain
nsaid
notabl
aspirin
alreadi
enter
clinic
trial
ibuprofen
also
regist
phase
ii
clinic
trial
therapi
xdr
modul
inflamm
tb
interf
cytokin
signal
anoth
promis
hdt
warrant
consider
fig
sever
strategi
congruent
divers
cytokin
involv
control
tb
inflamm
blockad
cytokin
signal
reduc
local
influx
inflammatori
cell
achiev
target
tnf
tnf
crucial
cytokin
immun
defenc
tb
although
requir
granuloma
integr
ltbi
high
level
tnf
exacerb
observ
pave
way
sever
hdt
approach
tnf
level
decreas
restrict
exacerb
patholog
altern
achiev
better
drug
penetr
lesion
destabil
solid
eventu
fibrot
granuloma
facilit
kill
mtb
resuscit
dormant
bacteria
replic
activ
given
link
cell
death
propag
inflammatori
respons
mtb
restrict
tnfinduc
necroptot
cell
death
infect
macrophag
deliveri
alisporivir
desipramin
could
limit
local
recruit
mtbpermiss
alisporivir
desipramin
restrict
rosmedi
necrosi
block
cyclophilin
acid
sphingomyelin
respect
tnf
blocker
wide
use
patient
rheumatoid
arthriti
inflammatori
bowel
diseas
thu
readili
repurpos
hdt
tb
sever
case
mab
tnf
infliximab
adalimumab
shown
benefici
effect
lifethreaten
etanercept
solubl
tnf
receptor
demonstr
modest
benefit
adjunct
therapi
howev
contrast
etanercept
mab
tnf
reactiv
ltbi
destabil
wherea
contraind
rheumatoid
arthriti
chronic
inflammatori
diseas
could
benefici
adjunct
therapi
tb
facilit
kill
metabol
activ
bacilli
may
repres
shock
kill
concentr
correl
sever
lung
damag
patient
revert
normal
concentr
upon
mab
inhibit
siltuximab
tocilizumab
clinic
use
rheumat
diseas
applic
biolog
associ
tb
reactiv
preclin
model
tb
therefor
one
hand
mab
pose
risk
reactiv
individu
ltbi
hand
suit
shock
kill
variou
class
drug
affect
tnf
signal
reactiv
ltbi
shown
potenti
hdt
tb
exampl
jak
inhibitor
tofacitinib
licens
patient
rheumatoid
arthriti
associ
reactiv
impair
bacillari
contain
murin
coadministr
tofacitinib
canon
chemotherapi
benefici
select
model
tb
suggest
activ
jak
inhibitor
influenc
pattern
inflamm
granulomat
addit
approach
modul
tnf
signal
abund
includ
thalidomid
phosphodiesteras
pde
thalidomid
improv
treatment
outcom
pilot
studi
pulmonari
howev
clinic
trial
test
adjunct
thalidomid
therapi
paediatr
tb
termin
owe
advers
event
includ
skin
rash
hepat
sever
neutropenia
thalidomid
teratogen
thalidomid
analogu
better
safeti
profil
synthes
analogu
inhibit
signal
increas
camp
level
shown
benefici
effect
adjunct
canon
tb
chemotherapi
mous
rabbit
model
compound
acceler
bacillari
clearanc
promot
lung
repair
pde
inhibitor
includ
cilostazol
inhibitor
sildenafil
inhibitor
show
similar
nonspecif
pde
inhibitor
pentoxifyllin
unsuccess
tb
trial
despit
reduc
tnf
level
induc
tb
progress
administ
monotherapi
mous
advanc
pde
inhibitor
preclin
studi
complet
phase
phase
ii
trial
plan
compar
mammalian
target
rapamycin
mtor
inhibitor
everolimu
thioredoxin
reductas
inhibitor
auranofin
vitamin
hdt
adjunct
standard
chemotherapi
acceler
cure
drugsensit
anoth
approach
restrict
local
inflamm
includ
codeliveri
glucocorticoid
receptor
agonist
prednisolon
dexamethason
tb
chemotherapi
effect
glucocorticoid
immun
cell
multifacet
corticosteroid
reduc
releas
proinflammatori
mediat
notabl
tnf
restrict
migrat
inflammatori
cell
caus
apoptosi
patient
tb
intervent
benefici
counteract
inflamm
like
improv
drug
penetr
granuloma
foster
clearanc
metabol
activ
mtb
consequ
lesion
destabil
adjunct
treatment
glucocorticoid
began
five
decad
ago
patient
differ
form
diseas
includ
tb
mening
tb
pericard
pulmonari
mani
case
corticosteroid
seem
improv
resolut
lesion
albeit
without
major
longterm
recent
metaanalysi
indic
glucocorticoid
receptor
agonist
mostli
reduc
tb
mortal
central
nervou
system
affect
notabl
tb
benefit
glucocorticoid
depend
genotyp
indic
diverg
effect
result
differ
pattern
inflamm
genotypespecif
hypo
hyperinflamm
differ
patient
influenc
mtb
replic
metaregress
analysi
pulmonari
tb
reveal
addit
genotyp
effect
dosag
corticosteroid
affect
sputum
convers
patient
phase
ii
clinic
trial
test
corticosteroid
combin
standard
chemotherapi
tb
patient
coinfect
hiv
indic
faster
sputum
convers
also
advers
event
high
studi
care
assess
risk
benefit
glucocorticoid
underway
deliveri
glucocorticoid
priorit
hdt
specif
patient
group
suffer
tb
aid
comorbid
use
prednison
nsaid
drug
meloxicam
prevent
immun
reconstitut
inflammatori
syndrom
iri
observ
patient
coinfect
hiv
mtb
reach
phase
iii
phase
ii
trial
stage
similarli
glucocorticoid
receptor
agonist
dexamethason
phase
iiiii
phase
iv
trial
therapi
mening
anticytokin
treatment
earli
hyperinflammatori
sepsi
sepsi
tradit
consid
disord
caus
uncontrol
exacerb
host
inflammatori
respons
invad
pathogen
concept
logic
given
patient
sepsi
frequent
present
sign
overwhelm
inflamm
typifi
highspik
fever
shock
acut
respiratori
distress
discoveri
tnf
cytokin
reinforc
concept
morbid
mortal
sepsi
due
unbridl
cytokinemedi
host
respons
fact
inhibitor
tnf
prevent
death
anim
model
sepsi
caus
endotoxin
escherichia
coli
support
idea
morbid
sepsi
due
excess
cytokinemedi
inflamm
patient
sepsi
quickli
succumb
overwhelm
cytokinemedi
hyperinflammatori
respons
typic
exampl
type
diseas
includ
meningococcaemia
rapidli
invas
necrot
soft
tissu
infect
group
streptococci
necrot
pneumonia
caus
leukocidinsecret
staphylococcu
aureu
overwhelm
clostridia
difficil
coliti
patient
type
toxinmedi
catastroph
infect
may
benefit
anticytokinebas
therapi
block
mediat
highli
lethal
acut
inflammatori
respons
howev
small
subset
patient
sepsi
therapi
use
block
host
respons
pathogen
short
act
appli
earli
sepsi
use
patient
sepsi
manifest
evid
uncontrol
inflamm
although
previou
trial
drug
inhibit
activ
tnf
fail
show
benefit
gener
popul
patient
sepsi
indic
particular
subset
patient
sepsi
may
benefici
regard
recent
reanalysi
deidentifi
data
phase
ii
trial
receptor
antagonist
anakinra
sever
sepsi
reveal
highli
signific
improv
surviv
subset
patient
concurr
hepatobiliari
dysfunct
dissemin
intravascular
coagul
dic
concomit
liver
injuri
dic
investig
specul
small
subset
patient
may
sepsisinduc
macrophag
activ
syndrom
character
uncontrol
macrophag
cell
activ
haemophagocytosi
mark
increas
circul
cytokin
hdt
target
inflamm
viral
infect
sepsi
share
similar
eritoran
agonist
well
advanc
clinic
trial
pipelin
either
aim
hyperinflammatori
phase
aim
system
effect
respect
antiinflammatori
strategi
inhibitor
intend
tb
viral
diseas
system
deliveri
glucocorticoid
immunosuppress
clinic
trial
tb
strategi
direct
toward
limit
granuloma
expans
instabl
rather
neoform
aim
augment
drug
penetr
lesion
balanc
inflammatori
respons
modifi
metabol
featur
immun
cell
facilit
tissu
repair
fig
supplementari
inform
tabl
spectrum
granuloma
differ
stage
patient
tb
demand
care
consider
spatiotempor
context
differ
approach
highlight
target
vascular
biolog
tb
granuloma
granuloma
reduc
blood
suppli
particularli
site
necrosi
therebi
restrict
access
chemotherapeut
site
mtb
infect
consequ
hdt
promot
vascular
perfus
improv
drug
deliveri
howev
strategi
may
equal
benefit
mtb
facilit
access
nutrient
permiss
host
cell
situat
somewhat
reminisc
neoplast
diseas
tumour
activ
promot
angiogenesi
improv
blood
suppli
allevi
local
hypoxia
late
stage
tumour
develop
outcom
vasculogenesisfocus
hdt
tb
like
depend
stage
diseas
treatment
object
name
interfer
either
angiogenesi
vascular
permeabl
patient
activ
tb
factor
induc
neovascular
notabl
vascular
endotheli
growth
factor
vegf
receptor
vegfr
abund
propos
biomark
diseas
bevacizumab
mab
vegf
approv
treatment
certain
cancer
sever
antibodi
target
vegf
vegfr
clinic
trial
anim
model
tb
vegf
vegfr
inhibitor
reveal
benefici
effect
given
combin
convent
drug
limit
bacteri
dissemin
boost
activ
drug
target
hypox
convers
risk
administr
biolog
without
concurr
chemotherapi
may
promot
tb
bacillari
addit
neovascular
vascular
dysfunct
emerg
anoth
common
cancer
tb
mtb
stimul
angiopoietin
axi
increas
blood
vessel
permeabl
vascular
endotheli
protein
tyrosin
phosphatas
inhibitor
molecul
close
relat
aerpio
therapeut
dephosphoryl
blunt
signal
endothelia
shown
restrict
mtb
replic
zebrafish
model
result
indic
hdt
strategi
modul
vascular
biolog
stabil
permeabl
vasculatur
independ
infectioninduc
neovascular
limit
bacteri
growth
dissemin
modul
bioenerget
tb
granuloma
granuloma
necrosi
cavit
hinder
access
chemotherapeut
agent
site
bacteri
replic
also
provid
microenviron
uniqu
physic
metabol
featur
oxygen
tension
gradual
decreas
granuloma
reach
hypox
valu
necrot
milieu
mtb
gain
increas
drug
resist
consequ
clonal
select
respons
local
monotherapi
owe
poor
drug
penetr
necrot
lesion
adjust
extracellular
addit
bacilli
switch
fatti
acidbas
metabol
adopt
persist
host
adapt
hypox
nutrientdepriv
microenviron
encompass
metabol
shift
oxid
phosphoryl
aerob
metabol
adjust
known
warburg
effect
well
establish
therapi
limit
aerob
glycolysi
includ
deliveri
antiglycolyt
agent
restrict
bioenerget
pathway
support
mtb
replic
moreov
interf
signal
pathway
inhibit
glutamin
entri
tricarboxyl
acid
tca
cycl
thu
revert
local
warburg
metabol
metformin
ampk
activ
thu
efficaci
hdt
goe
beyond
effect
macrophag
discuss
potenti
interfer
immun
metabol
granuloma
less
wellexplor
still
interest
bioenerget
shift
encompass
gener
itacon
acid
structur
analogu
succin
control
tca
remodel
macrophag
antimycobacteri
addit
metabol
chang
granuloma
lead
accumul
advanc
glycat
end
product
age
affect
macrophag
death
age
detect
tb
granuloma
pathway
regul
gener
age
could
potenti
hdt
target
promot
tissu
repair
granuloma
format
regress
lesion
occur
concurr
infect
tissu
balanc
tissu
repair
exacerb
patholog
depend
net
abund
mediat
matrix
metalloproteinas
mmp
caus
lung
patholog
factor
regul
mediat
tissu
inhibitor
metalloproteinas
timp
genet
associ
studi
support
crucial
role
mmp
lesion
zincdepend
proteas
mainli
cleav
extracellular
matrix
mostli
collagen
link
earli
granuloma
format
lesion
progress
antibiot
doxycyclin
inhibit
therebi
restrict
exacerb
inflamm
tissu
damag
deliveri
doxycyclin
limit
immunopatholog
promot
tissu
heal
lung
repair
doxycyclin
welldefin
pharmacokinet
pharmacodynam
profil
owe
broad
use
antiinfect
drug
may
therefor
potenti
rapidli
repurpos
tb
mmp
inhibitor
batimastat
marimastat
well
deserv
evalu
tb
howev
drug
show
advers
effect
musculoskelet
system
upon
prolong
administr
therebi
question
overal
benefit
tb
therapi
hdt
interfer
host
cell
mechan
enhanc
immun
respons
reduc
exacerb
inflamm
balanc
host
reaction
site
patholog
hold
enorm
promis
select
symptomat
treatment
infecti
diseas
viral
infect
target
host
cell
factor
pathway
requir
given
viru
product
replic
spread
offer
opportun
broadspectrum
antivir
drug
futur
activ
focu
identif
suitabl
host
cell
factor
pathway
commonli
use
differ
virus
particularli
pandem
potenti
although
relev
inform
gener
recent
genet
screen
knowledg
remain
limit
equal
promis
hdt
aim
control
exacerb
inflamm
tissu
damag
discuss
approach
applic
numer
viral
bacteri
infect
could
use
adjunct
therapi
combin
select
pathogentarget
approach
pathway
involv
inflamm
well
understood
drug
alreadi
avail
allow
rapid
repurpos
infecti
diseas
control
accordingli
drug
current
hdt
clinic
trial
fall
categori
biomark
becom
essenti
part
futur
therapi
regim
henc
must
becom
integr
compon
r
activ
target
infecti
diseas
whether
host
pathogen
direct
biomark
indic
stage
infect
allow
monitor
treatment
success
failur
provid
inform
organ
involv
type
inflamm
permit
patient
stratif
select
hdt
person
regim
particularli
import
treatment
sepsi
advanc
immunophenotyp
allow
physician
determin
whether
patient
hyper
hypoinflammatori
phase
disord
select
appropri
immunotherapi
similarli
hyper
hypoinflammatori
lesion
coexist
tb
thu
requir
person
treatment
regim
addit
capac
identifi
particular
defect
innat
adapt
immun
immun
profil
cell
exhaust
increas
frequenc
regulatori
cell
myeloidderiv
suppressor
cell
mdsc
enabl
person
approach
correct
similar
impress
advanc
made
oncolog
combin
immunotherapi
hold
great
promis
next
major
advanc
infecti
diseas
moreov
identif
potenti
genet
predisposit
patient
instruct
adjunct
hdt
case
tb
genet
condit
lipid
mediat
mutat
enzymecod
gene
particularli
overproduct
link
tnf
abund
affect
outcom
immunosuppress
therapi
patient
tb
macrophag
major
target
hdt
tb
target
myeloid
cell
subset
neutrophil
also
contain
bacilli
associ
poor
diseas
may
lead
novel
approach
hdt
although
forese
bright
futur
hdt
newli
emerg
treatment
option
misinterpret
exclus
altern
rather
envisag
synergist
addon
canon
antiinfect
undoubtedli
futur
treatment
regimen
infecti
diseas
converg
concept
person
medicin
provid
best
possibl
combin
adjust
pathogen
also
patient
howev
clinic
benefit
socioeconom
effect
healthcar
system
would
impos
higher
cost
approach
remain
determin
moreov
hdt
adjunct
strategi
treatment
infect
infanc
requir
indepth
analysi
possibl
cytotox
potenti
worsen
infect
respect
hdt
also
requir
novel
think
side
drug
develop
side
legal
author
respons
approv
drug
nevertheless
given
progress
made
past
year
combin
canon
pathogendirect
novel
hostdirect
like
becom
indispens
springer
natur
remain
neutral
regard
jurisdict
claim
publish
map
institut
affili
